AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
2.580
+0.010 (0.39%)
Sep 10, 2025, 10:48 AM - Market open
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$5,261
Profits / Employee
-$702,870
Market Cap
6.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | -5 | -17.86% |
| Dec 31, 2023 | 28 | 4 | 16.67% |
| Dec 31, 2022 | 24 | 1 | 4.35% |
| Dec 31, 2021 | 23 | 0 | - |
| Dec 31, 2020 | 23 | -3 | -11.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AIM News
- 6 days ago - AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland - GlobeNewsWire
- 20 days ago - AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 26 days ago - AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 27 days ago - AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval - GlobeNewsWire
- 6 weeks ago - Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
- 2 months ago - AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies - GlobeNewsWire